Ceramedix Holding, LLC

New York, NY · Biotech · Private

Anti-ceramide monoclonal antibody fragment (CX-01) therapeutic for radiation-induced gastrointestinal acute radiation syndrome

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: New York, NY
Total capital: $16.2M

Federal grants: $6M; 6 awards · 2018–2025; Rank in peer group#113 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $10.2M; 3 awards · Defense, Health and Human S; Rank in Biotech#59 of 4373
Granted patents: 1; 2 pending · first 2026; Rank in peer group#186 of 514

Capital timeline

Latest events

Jul 2026Federal contractHealth and Human S · Development Of Radiation/nuclear Medical Countermeasures (mcms) And Biodosimetry Devices. 7-1/2026 To 6/30/2026. DAP-NCAP-00000073.$1.5M
Jan 2025Federal grantHealth and Human S · Phase II · Non-Clinical Pharmacology of CX-01$993K
Feb 2024Federal grantHealth and Human S · Phase II · Non-Clinical Pharmacology of CX-01$1M
Jul 2023Federal contractHealth and Human S · Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure$4.2M
Feb 2023Federal grantHealth and Human S · Phase II · Non-Clinical Pharmacology of CX-01$1M
Sep 2020Federal contractDefense · JW190496 FY19 New Start$4.5M
Apr 2020Federal grantHealth and Human S · Phase II · Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome$994K

Show 2 earlier federal awards

Apr 2019Federal grantHealth and Human S · Phase II · Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome$968K
Apr 2018Federal grantHealth and Human S · Phase II · Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome$993K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#113 · top 22%
Granted patents#186 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 3

Jun 16, 2026GrantedAnti-ceramide AntibodiesUSPTOUS 12,655,229
PendingAnti-ceramide AntibodiesUSPTOApplication PCTUS2021022914
PendingAnti-ceramide AntibodiesUSPTOApplication 62991232

INOVIO PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12M in contracts
Twist BioscienceSimilar federal contract value in Biotech · $12M in contracts
Codagenix Inc.Similar federal contract value in Biotech · $11.2M in contracts
SACHI BIOWORKS, INC.Similar federal contract value in Biotech · $9.8M in contracts
INNOVATION PATHWAYS, LLCSimilar federal contract value in Biotech · $9.2M in contracts
Noveome Biotherapeutics, Inc.Similar federal contract value in Biotech · $8.5M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.